Biology of hepatic cancer stem cells

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 8, 2011, Pages 1229-1237

  Tong, Carol Man ^a   Ma, Stephanie ^a,b   Guan, Xin Yuan ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer stem cells; Chemoresistance; Hepatocellular carcinoma; Liver cancer; MiRNA; Self renewal; Tumor initiating cells

Indexed keywords

ABCB5 PROTEIN; ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; AURISTATIN F; BAG 1 PROTEIN; BESTATIN; BETA CATENIN; BMI1 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIBODY; CD133 ANTIGEN; CD44 ANTIBODY; CD44V ANTIGEN; CISPLATIN; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; GROWTH FACTOR; LUPEOL; MICRORNA; MICRORNA 181; MICRORNAB; MICROSOMAL AMINOPEPTIDASE; OCTAMER TRANSCRIPTION FACTOR 4; ONCOSTATIN M; PROTEIN KINASE B; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN;

ANGIOGENESIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL POPULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CELL CARCINOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 79960439415     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06762.x     Document Type: Article

References (48)

1. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8.
2. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 2007; 23: 675-99.
3. Lapidot T, Sirard C, Vormoor J etal. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994; 367: 645-8.
4. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008; 8: 755-68.
5. Visvader JE. Cells of origin in cancer. Nature 2011; 469: 314-22.
6. Zhou BB, Zhang H, Damelin M etal. Tumor-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009; 8: 806-23.
7. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
8. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis. 2010; 30: 61-74.
9. Goodell MA, Brose K, Paradis G etal. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 1996; 183: 1797-806.
10. Chiba T, Kita K, Zheng YW etal. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44: 240-51.
11. Hill RP. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res. 2006; 66: 1891-5.
12. + hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem. Biophys. Res. Commun. 2006; 351: 820-4.
13. Yin S, Li J, Hu C etal. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer 2007; 120: 1444-50.
14. Ma S, Chan KW, Hu L etal. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542-56.
15. + liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010; 7: 694-707.
16. Song W, Li H, Tao K etal. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int. J. Clin. Pract. 2008; 62: 1212-18.
17. Kastan MB, Schlaffer E, Russo JE, Colvin OM, Civin CI, Hilton J. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990; 75: 1947-50.
18. Pearce DJ, Taussig D, Simpson C etal. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005; 23: 752-60.
19. Ginestier C, Hur MH, Charafe-Jauffret E etal. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-67.
20. Ma S, Chan KW, Lee TK etal. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol. Cancer Res. 2008; 6: 1146-53.
21. Dalerba P, Dylla SJ, Park IK etal. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U. S. A. 2007; 104: 10158-63.
22. Yang ZF, Ngai P, Ho DW etal. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008; 47: 919-28.
23. + cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-66.
24. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 3983-8.
25. Zhu Z, Hao X, Yan M etal. Cancer stem/progenitor cells are highly enriched in CD133(+)CD44(+) population in hepatocellular carcinoma. Int. J. Cancer 2010; 126: 2067-78.
26. Yamashita T, Forgues M, Wang W etal. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008; 68: 1451-61.
27. Kim JW, Ye Q, Forgues M etal. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 2004; 39: 518-27.
28. Yamashita T, Ji J, Budhu A etal. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-24.
29. Haraguchi N, Ishii H, Mimori K etal. CD13 is a therapeutic target in human liver cancer stem cells. J. Clin. Invest. 2010; 120: 3326-39.
30. + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008; 27: 1749-58.
31. Yamashita T, Honda M, Nio K etal. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-fluorouracil by inducing hepatocytic differentiation. Cancer Res. 2010; 70: 4687-97.
32. Wang XQ, Ongkeko WM, Chen L etal. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP binding cassette G2 pathway. Hepatology 2010; 52: 528-39.
33. Cheung ST, Cheung PF, Cheng CK, Wong NC, Fan ST. Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate live cancer cell chemoresistance. Gastroenterology 2011; 140: 344-55.
34. Chiba T, Zheng YW, Kita K etal. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 2007; 133: 937-50.
35. Chiba T, Miyagi S, Saraya A etal. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res. 2008; 68: 7742-9.
36. Yang W, Yan HX, Chen L etal. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 2008; 68: 4287-95.
37. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007; 67: 10831-9.
38. Tang Y, Kitisin K, Jogunoori W etal. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc. Natl. Acad. Sci. U. S. A. 2008; 105: 2445-50.
39. You H, Ding W, Rountree CB. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010; 51: 1635-44.
40. Esquela-Kerscher A, Slack FJ. Oncomirs- microRNAs with a role in cancer. Nat. Rev. Cancer 2006; 6: 259-69.
41. Law PT, Wong N. Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2011; 26: 437-49.
42. deSano JT, Xu L. microRNA regulation of cancer stem cells and therapeutic implications. AAPS J. 2009; 11: 682-92.
43. Ji J, Yamashita T, Budhu A etal. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009; 50: 472-80.
44. Budhu A, Jia HL, Forgues M etal. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008; 47: 897-907.
45. Yang XR, Xu Y, Yu B etal. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumor angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 2010; 59: 953-62.
46. Smith LM, Nesterova A, Ryan MC etal. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br. J. Cancer 2008; 99: 100-9.
47. Ho JC, Ip YC, Cheung ST etal. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 2008; 47: 1524-32.
48. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 2011; 53: 160-70.